16 May 2025 · Ziconotide products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
11 August 2022 · Vancomycin products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
11 August 2022 · Trastuzumab products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
11 August 2022 · Topotecan products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
11 August 2022 · Thiotepa products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
19 December 2024 · Provision of intrathecal and epidural injections in NRFit syringes may involve extrapolation of stability data from luer lock systems
11 August 2022 · Ropivacaine products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
11 August 2022 · Rituximab products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
11 August 2022 · Phenol products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
24 May 2010 · This audit document is intended to be used to audit Pharmacy aspects of the safe administration of intrathecal chemotherapy, as part of the EL(97)52 Audit…